This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
61-50-7Relevant articles and documents
ALKALOIDS FROM THE HALLUCINOGENIC PLANT VIROLA SEBIFERA
Kawanishi, K.,Uhara, Y.,Hashimoto, Y.
, p. 1373 - 1376 (1985)
Key Word Index - Virola sebifera; Myristicaceae; hallucinogenic plant; alkaloids; N-methyl-N-acetyltryptamine; N-methyl-N-formyltryptamine; 2-methyl-1,2,3,4-tetrahydro-β-carboline; N,N-dimethyltryptamine; N,N-dimethyltryptamine-N-oxide; N-monomethyltryptamine. - Bark of Virola sebifera used in the preparation of hallucinogenic snuffs and drinks in Venezuela has yielded N-methyl-N-formyltryptamine and N-methyl-N-acetyltryptamine, which exist in two rotameric forms reflecting hindered rotation around the carbon-nitrogen bond of the amide function.They were detected by HPLC as well as NMR. 2-Methyl-1,2,3,4-tetrahydro-β-carboline, N,N-dimethyltryptamine, its oxide and N-monomethyltryptamine were also identified.
Successful bridging from a peptide to a non peptide antagonist at the human tachykinin NK-2 receptor
Altamura, Maria,Canfarini, Franca,Catalioto, Rose-Marie,Guidi, Antonio,Pasqui, Franco,Renzetti, Anna R.,Triolo, Antonio,Maggi, Carlo A.
, p. 2945 - 2948 (2002)
Non peptide products have been found to show nanomolar binding and functional affinities at the human tachykinin NK-2 receptor. The new antagonists do not possess stereogenic centers and their thermal behaviour in solution is featured by a peculiar set of conformational stereoisomers. A macroscopic viewpoint is preferentially adopted to rationalize the obtained results.
THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS
-
Page/Page column 24, (2020/12/29)
The present invention relates to compositions comprising N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and/or partially deuterated N,N-dimethyltryptamine. In particular, the present invention relates to compositions comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N- dimethyltryptamine compound selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compound selected from α,β,β-trideutero-N,N-dimethyltryptamine, α,β-dideutero-N,N- dimethyltryptamine, and α-deutero-N,N-dimethyltryptamine. Methods of synthesising compositions of the present invention, and methods of use of presently described compositions in treating psychiatric or psychocognitive disorders, such as major depressive disorder, are also provided.
Indole derivatives and its application on the medicament
-
Paragraph 0222; 0224-0227; 0294; 0296-0299, (2019/03/28)
The invention provides indole derivatives or stereisomers, tautomers, nitrogen oxides, solvate, metabolic products, pharmaceutically acceptable salts or prodrugs thereof for treating the alzheimer disease. The invention further discloses a pharmaceutical composition containing the compounds and a method of using the compounds or the pharmaceutical composition thereof to treat the alzheimer disease.
Well-Defined Phosphine-Free Iron-Catalyzed N-Ethylation and N-Methylation of Amines with Ethanol and Methanol
Lator, Alexis,Gaillard, Sylvain,Poater, Albert,Renaud, Jean-Luc
supporting information, p. 5985 - 5990 (2018/10/02)
An iron(0) complex bearing a cyclopentadienone ligand catalyzed N-methylation and N-ethylation of aryl and aliphatic amines with methanol or ethanol in mild and basic conditions through a hydrogen autotransfer borrowing process is reported. A broad range of aromatic and aliphatic amines underwent mono- or dimethylation in high yields. DFT calculations suggest molecular hydrogen acts not only as a reducing agent but also as an additive to displace thermodynamic equilibria.